Navegando por Palavras-chave "itraconazole"
Agora exibindo 1 - 8 de 8
Resultados por página
Opções de Ordenação
- ItemSomente MetadadadosCase report. Histoplasmosis in an AIDS paediatric patient(Blackwell Wissenschafts-verlag Gmbh, 1999-11-01) Cimerman, S.; Sokolowski, W.; Goncalves, SEC; Lins, MSD; Colombo, A. L.; Universidade Federal de São Paulo (UNIFESP)Histoplasmosis has been little reported among HIV-infected children. We report a case of a 4-year old boy with AIDS who presented with disseminated histoplasmosis diagnosed by lung biopsy. the patient had a good clinical response to amphotericin B followed by itraconazole oral solution.
- ItemSomente MetadadadosClotrimazole is highly effective in vitro against feline Sporothrix brasiliensis isolates(Microbiology Soc, 2017) Gagini, Thalita; Borba-Santos, Luana Pereira; Rodrigues, Anderson Messias [UNIFESP]; de Camargo, Zoilo Pires [UNIFESP]; Rozental, SoniaPurpose. Sporothrix brasiliensis, the most virulent species in the Sporothrix schenckii complex, is responsible for the ongoing epidemics of human and animal sporotrichosis in Brazil. Feline outbreaks are usually driven by S. brasiliensis and followed by extensive transmission to humans. Itraconazole is the first-line treatment for both feline and human sporotrichosis; however, reduced sensitivity is an emerging issue. Thus, we investigated the effect of the widely used antifungal clotrimazole - alone or in combination with itraconazole - against the pathogenic (yeast) form of feline and human S. brasiliensis isolates, in vitro. Methodology. Minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) values were determined for treatment with clotrimazole and itraconazole, as monotherapy or in combination. In addition, the effect of the drugs on neutral lipid levels and the yeast ultrastructure were evaluated by flow cytometry and transmission electron microscopy (TEM), respectively. Results. The MIC and MFC values show that clotrimazole was more effective than itraconazole against feline S. brasiliensis isolates, while human isolates were more sensitive to itraconazole. Similarly to itraconazole, treatment with clotrimazole induced statistically significant neutral lipid accumulation in S. brasiliensis yeasts, and treated yeasts displayed irregularities in the cell membrane and a thicker cell wall when observed by TEM. Clotrimazole increased the antifungal activity of itraconazole in combination assays, with a synergistic effect for two feline isolates. Conclusion. The strong activity of clotrimazole against feline S. brasiliensis isolates suggests that this drug is potentially a new alternative for the treatment of feline sporotrichosis, alone or in combination with itraconazole.
- ItemSomente MetadadadosDermatophytosis on the eyelid caused by Microsporum gypseum(Blackwell Verlag Gmbh, 2005-01-01) Machado, A. P.; Hirata, S. H.; Ogawa, M. M.; Tomimori-Yamashita, J.; Fischman, O.; Universidade Federal de São Paulo (UNIFESP)We report a case of tinea on the eyelid in a woman with psoriasis. Due to the history of psoriasis and clinical aspect of the lesion the diagnosis of psoriasis was suggested in the first place; however, laboratory examination revealed Microsporum gypseum. the patient was treated with oral itraconazole resulting in clinical and mycological cure. We emphasize the uncommon location of tinea caused by M. gypseum and the importance of searching for fungal infection on scaly lesions.
- ItemAcesso aberto (Open Access)Evaluation of efficacy and safety of itraconazole oral solution for the treatment of oropharyngeal candidiasis in AIDS patients(Brazilian Society of Infectious Diseases, 2001-04-01) Queiroz-Telles, Flávio de; Silva, Nanci; Carvalho, Miriam M.; Alcântara, Ana Paula; Matta, Daniel Archimedes da [UNIFESP]; Barberino, Maria G.; Bartczak, Sergio; Colombo, Arnaldo Lopes [UNIFESP]; Federal University of Paraná Clinical Hospital; Aliança Hospital; Universidade Federal de São Paulo (UNIFESP); Janssen-Cilag Farmacêutica do BrasilThis study was a non-comparative multicenter clinical trial to evaluate the efficacy and tolerability of itraconazole oral solution 200 mg/day (100 mg twice a day in the fasting state) for the treatment of oropharyngeal candidiasis in AIDS patients. We included 50 patients who were treated and followed for up to 3 weeks after ending therapy in the analysis. Mycological cures at the end of therapy occurred in 20/50 patients (40%), but colonization by Candida sp. was recorded in 42/50 (84%) by the end of follow-up. A high rate of clinical response was observed in 46/50 (92%), and the response was sustained for up to 21 days after stopping therapy in 24/46 patients (52%). Clinical relapses were documented among 22 patients, but all causative fungal organisms associated with a relapse were susceptible to itraconazole. There were many patients with persistence or recurrence of Candida, but without mucositis. Relapse of Candida mucositis was significantly related to low levels of CD4 lymphocytes exhibited by symptomatic patients. The drug was well tolerated by all but 1 patient. We conclude that itraconazole oral solution (100 mg bid for 7-14 days) is a well tolerated and effective treatment for suppressing the symptoms of oropharyngeal candidiasis in AIDS patients. Patients with severe immunosuppression may relapse and require frequent cycles of treatment or longterm suppressive therapy.
- ItemSomente MetadadadosItraconazole versus terbinafine (LAMISIL (R)): which is better for the treatment of onychomycosis?(Elsevier B.V., 1997-12-01) Honeyman, J. F.; Talarico, S.; Arruda, LHF; Pereira, A. C.; Santamaria, JR; Souza, E. M.; Woscoff, A.; Amorim, R.; De la Parra, C. R.; Enokihara, M. Y.; Gavazoni, M. F.; Gubelin, H. W.; Rosa, S. P.; Turini, MAG; Vitale, M. A.; Univ Chile; Universidade Federal de São Paulo (UNIFESP); Fac Med Jundial; Universidade Federal do Rio de Janeiro (UFRJ); Parana Hosp Evangelico Curitiba; Dermatol Clin; Univ Buenos AiresObjectives To compare the efficacy, safety and tolerability of oral terbinafine with itraconazole in patients with toenail onychomycosis treated for 4 months.Setting Departments of dermatology of six universities and one private clinic.Design Double-blind double-dummy, multicentric, multinational, parallel-group therapeutic trial, involving 179 patients with toenail onychomycosis. Patients were randomly treated with either 200 mg/day oral itraconazole or 250 mg/day terbinafine for 4 months, After the 4th month both treatment groups received oral placebo for another 8 months. the total duration of the study was therefore 12 months. After the 12th month a final evaluation of efficacy was performed in 167 patients (85 on itraconazole and 82 on terbinafine) and a final evaluation of tolerability was performed in 175 patients.Results the dermatophytes identified at the initial visit were Trichophyton rubrum (82.1%), Trichophyton mentagrophytes (14%) and others (3.9%). the mycological cure rates at the end of the 4th and 12th months were 54.9% and 95.3% in the terbinafine,stoup and 51.8% and 84.3% in the itraconazole group (the difference between the groups was statistically significant at the 12th month, P < 0.04). Clinical cure was achieved by 8.5% and 9.4% of the patients in the terbinafine and itraconazole groups at the 4th month (not significant, NS) and these rates increased to 57.8% and 62.9%, respectively, at the 12th month (difference between groups NS, P > 0.05). A complete mycological cure associated with clinical improvement over 50%, was observed at the 4th month in 50% of the patients treated with terbinafine and 49.4% of the patients treated with itraconazole which was not statistically significant (NS). At the 12th month the rates increased to 95.4% with terbinafine and 75.7% with itraconazole (statistically significant, P < 0.001). Seven patients of the terbinafine group and 9 patients of the itraconazole group presented drug-related side effects (NS). Six patients (6.3%) discontinued the study due to adverse events in the itraconazole group but no patient discontinued in the terbinafine group. At entry into the study all subjects in both groups presented normal values in liver function tests which remained unchanged throughout the study in the patients of the terbinafine group, One patient of the itraconazole group presented small increases in SOOT and SGPT associated with abdominal pain and nausea.Conclusion Although both itraconazole and terbinafine were effective, well tolerated and safe, terbinafine demonstrated a higher rate of efficacy in the long run after treatment was stopped. (C) 1997 Elsevier Science B.V.
- ItemSomente MetadadadosMycoses of implantation in Latin America: an overview of epidemiology, clinical manifestations, diagnosis and treatment(Informa Healthcare, 2011-04-01) Queiroz-Telles, Flavio; Nucci, Marcio; Colombo, Arnaldo Lopes [UNIFESP]; Tobon, Angela; Restrepo, Angela; Univ Fed Parana; Universidade Federal do Rio de Janeiro (UFRJ); Universidade Federal de São Paulo (UNIFESP); Corp Invest BiolImplantation or subcutaneous mycoses are a frequent health problem in Latin American countries and other tropical and subtropical areas. Although such infections rarely cause disseminated or invasive disease, they have an important impact on public health, and timely diagnosis and appropriate treatment remain important. Although some implantation mycoses are found in immunocompromised persons, the immunocompetent population is the principal target in Latin America. Most etiologic agents are found in soil, vegetation, and decaying matter in tropical, subtropical, and humid environments and infection is commonly the result of penetrating injury. Infections primarily occur (1) among low socioeconomic groups, (2) among those living in rural areas or involved in farming, hunting, or other outdoor activities, and (3) particularly among adult men. This review focuses on the epidemiology of the most clinically significant implantation mycoses in Latin America, i.e., sporotrichosis, eumycetoma, chromoblastomycosis, subcutaneous phaeohyphomycosis, subcutaneous zygomycosis, and lacaziosis. Main epidemiologic findings, clinical manifestations, diagnosis, and treatment options are also discussed.
- ItemSomente MetadadadosTreatment of subcutaneous phaeohyphomycosis and prospective follow-up of 17 kidney transplant recipients(Elsevier B.V., 2009-12-01) Ogawa, Marilia Marufuji [UNIFESP]; Galante, Nelson Zocoler [UNIFESP]; Godoy, Patricio [UNIFESP]; Fischman-Gompertz, Olga [UNIFESP]; Martelli, Flavia [UNIFESP]; Colombo, Arnaldo Lopes [UNIFESP]; Tomimori, Jane [UNIFESP]; Medina-Pestana, Jose Osmar [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)Background: Subcutaneous phaeohyphomycosis in solid organ recipients may have an adverse outcome.Objective. We sought to describe the disease course, treatment, and outcome of allograft function in kidney transplant recipients with phaeohyphomycosis.Methods: Seventeen patients were followed for a mean period of 25.4 months to analyze the clinical response to treatment.Results: There was no treatment failure or relapsing disease among 12 patients who completed treatment. Two patients were still in treatment with disease remission. One patient discontinued the study during treatment with partial remission, one died after finishing treatment with disease remission, and one was dropped from the study because contact was lost. Immunosuppresive regimens were not changed. Two of 17 patients had a significant reduction in allograft function.Limitations: the follow-up time was short and the number of patients was small.Conclusions. the outcome of phaeohyphomycosis in kidney transplant recipients was favorable with minimal impact on renal allograft function. (J Am Acad Dermatol 2009;61:977-85.)
- ItemSomente MetadadadosTreatment options for paracoccidioidomycosis and new strategies investigated(Expert Reviews, 2008-04-01) Travassos, Luiz R. [UNIFESP]; Taborda, Carlos Pelleschi [UNIFESP]; Colombo, Arnaldo L. [UNIFESP]; Universidade Federal de São Paulo (UNIFESP); Universidade de São Paulo (USP)Paracoccidioidomycosis is the most prevalent systemic endemic mycosis in South America with most reported cases in Brazil. It is a major cause of disability and death among young adult rural workers during their most productive years of life. Sequels are frequent and the evolution of the disease and mortality burden are strongly influenced by the socio-economic status of the patients. Although long periods of antifungal therapy (sulfamethoxazole/trimethoprim, itraconazole and amphotericin B) are used in clinical practice, relapses remain a significant unresolved problem. Early diagnosis is hampered by structural factors, ranging from the high costs of reagents, the lack of trained personnel and limited access to the healthcare system by rural workers. A peptide vaccine aimed at immunotherapy of paracoccidioidomycosis, as an adjuvant to chemotherapy, is being studied. the protective effects obtained in mice intratracheally infected with Paracoccidioides brasiliensis, and the promiscuous binding of the peptide P10 to HLA-DR molecules, suggest that it could be used as a vaccine to reduce the duration of chemotherapy and the risk of relapse.